Prehospitalization inhaled corticosteroid use in patients with COPD or asthma

Chest

Volumn 111, Issue 2, 1997, Pages 296-302

  Jackevicius, Cynthia ^a   Joyce, David P ^a   Kesten, Steven ^b   Chapman, Kenneth R ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; IPRATROPIUM BROMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; THEOPHYLLINE;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG COST; DRUG FORMULATION; FEMALE; HOSPITALIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OSTEOPENIA; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0031020213     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.111.2.296     Document Type: Article

References (29)

1. Hargreave FE, Dolovich J, Newhouse MT. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol 1990; 85:1098-1111
2. Murata GH, Gorby MS, Chick TW, et al. Intravenous and oral corticosteroids for the prevention of relapse after treatment of decompensated COPD: effect on patients with a history of multiple relapses. Chest 1990; 98:845-49
3. Weir DC, Gove RI, Robertson AS, et al. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral and inhaled beclomethasone dipropionate. Thorax 1990; 45:112-17
4. Postma DS, Steenhuis EJ, Van der Weele LT, et al. Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985; 67:56-64
5. Postma DS, Peters I, Steenhuis EJ, et al. Moderately severe chronic airflow obstruction: can corticosteroids slow down obstruction? Eur Respir J 1988; 1:22-6
6. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991; 114:216-23
7. Auffarth B, Postma DS, de Monchy JGR, et al. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax 1991; 46:372-77
8. Engel T, Heinig JH, Madsen O, et al. A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis. Eur Respir J 1989; 2:935-39
9. Shim CS, Williams MH. Aerosol beclomethasone in patients with steroid-responsive chronic obstructive pulmonary disease. Am J Med 1985; 78:655-58
10. Thompson AB, Mueller MB, Heires AJ, et al. Aerosolized beclomethasone in chronic bronchitis. Am Rev Respir Dis 1992; 146:389-95
11. Kerstjens HAM, Brand PLP, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992; 327:1413-19
12. Robertson AS, Gove GA, Wieland P. A double-blind comparison of oral prednisolone 40 mg/day with inhaled beclomethasone dipropionate 1500 μg/day in patients with adult onset chronic obstructive airways disease. Eur J Respir Dis 1986; 146 (suppl):565-69
13. Watson A, Lim TK, Joyce H, et al. Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. Chest 1992; 101:350-55
14. Weiner P, Weiner M, Azgad Y, et al. Inhaled budesonide therapy for patients with stable COPD. Chest 1995; 108: 1568-71
15. Chapman KR, Bowie DM, Hodder RV, et al. Guidelines for the assessment and management of chronic obstructive pulmonary disease: Canadian Thoracic Society Working Group. Can Med Assoc J 1992; 147:420-28
16. Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-121
17. Siafakis NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8:1398-1420
18. Kesten S, Rebuck AS, Chapman KR. Trends in asthma and chronic obstructive pulmonary disease therapy in Canada, 1985 to 1990. J Allergy Clin Immunol 1993; 92:499-506
19. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest 1993; 104:254-58
20. Shim CS, Williams MH Jr. Aerosol beclomethasone in patients with steroid-responsive chronic obstructive pulmonary disease. Am J Med 1985; 78:655-58
21. Harding SM, Freedman S. A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response. Thorax 1978; 33:214-18
22. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984; 129:856-70
23. Pakes GE, Brogden RN, Heel RC, et al. Ipratropium bromide: a review of its pharmacologic properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980; 20:237-66
24. Gross NJ. Anticholinergic agents in COPD. Chest 1987; 91 (suppl 5):52S-7S
25. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995; 98:196-208
26. Hanania NA, Chapman KR, Sturtridge WC, et al. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995; 96:571-79
27. Pauwels RA, Lofdahl C, Pride NB, et al. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992; 5:1254-61
28. Dodge RR, Burrows B. The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 1980; 122:567-75
29. Mendella LA, Manfreda J, Warren CPW, et al. Steroid response in chronic obstructive pulmonary disease. Ann Intern Med 1982; 96:17-21